←ABBV · $264.04

AbbVie

ABBV · Market closed

$264.04

-0.63% today·exchange $264.04

exchange $264.04

Sep 15$255.18 – $267.62Sep 24

1D 1W 1M 1Y

News · AbbVie

Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade
Motley Fool · 2h ago
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO
Insider Monkey · 12h ago
What Is AbbVie No Longer Telling You?
Trefis · 14h ago
What Is The Best Case For Pfizer Stock?
Trefis · 14h ago
AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis
Simply Wall St. · 22h ago
AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still Matters
Insider Monkey · 1d ago

Headlines from Yahoo Finance. Not investment advice.

About

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Industry: Healthcare
CEO: Robert A. Michael